Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation

Agnieszka Czechowicz; Rahul Palchaudhuri; Amelia Scheck; Yu Hu; Jonathan Hoggatt; Borja Saez; Wendy W. Pang; Michael K. Mansour; Tiffany A. Tate; Yan Yi Chan; Emily Walck; Gerlinde Wernig; Judith A. Shizuru; Florian Winau; David T. Scadden; Derrick J. Rossi

doi:10.1038/s41467-018-08201-x

Nature Communications (Feb 2019)

Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation

Agnieszka Czechowicz,
Rahul Palchaudhuri,
Amelia Scheck,
Yu Hu,
Jonathan Hoggatt,
Borja Saez,
Wendy W. Pang,
Michael K. Mansour,
Tiffany A. Tate,
Yan Yi Chan,
Emily Walck,
Gerlinde Wernig,
Judith A. Shizuru,
Florian Winau,
David T. Scadden,
Derrick J. Rossi

Affiliations

Agnieszka Czechowicz: Program in Cellular and Molecular Medicine, Department of Medicine, Boston Children’s Hospital
Rahul Palchaudhuri: Department of Stem Cell and Regenerative Biology, Harvard University
Amelia Scheck: Program in Cellular and Molecular Medicine, Department of Medicine, Boston Children’s Hospital
Yu Hu: Program in Cellular and Molecular Medicine, Department of Medicine, Boston Children’s Hospital
Jonathan Hoggatt: Department of Stem Cell and Regenerative Biology, Harvard University
Borja Saez: Department of Stem Cell and Regenerative Biology, Harvard University
Wendy W. Pang: Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine
Michael K. Mansour: Department of Stem Cell and Regenerative Biology, Harvard University
Tiffany A. Tate: Department of Stem Cell and Regenerative Biology, Harvard University
Yan Yi Chan: Department of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine, Stanford University School of Medicine
Emily Walck: Department of Pediatrics, Division of Stem Cell Transplantation and Regenerative Medicine, Stanford University School of Medicine
Gerlinde Wernig: Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine
Judith A. Shizuru: Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine
Florian Winau: Program in Cellular and Molecular Medicine, Department of Medicine, Boston Children’s Hospital
David T. Scadden: Department of Stem Cell and Regenerative Biology, Harvard University
Derrick J. Rossi: Program in Cellular and Molecular Medicine, Department of Medicine, Boston Children’s Hospital

DOI: https://doi.org/10.1038/s41467-018-08201-x
Journal volume & issue: Vol. 10, no. 1
pp. 1 – 12

Abstract

Read online

Hematopoietic stem cell (HSC) transplantation is a desirable treatment for many non-malignant and malignant diseases, but its use requires preconditioning of recipients with irradiation or chemotherapy that often induces high toxicity. Here the authors show that antibody-drug-conjugate to CD117, a HSC marker, allows specific and efficient preconditioning for HSC therapy.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal